A type I IFN, prothrombotic hyperinflammatory neutrophil signature is distinct for COVID-19 ARDS­­­

10.12688/wellcomeopenres.16584.1

Wellcome Open Research

Contributing to research themes:

Abstract

Background: Acute respiratory distress syndrome (ARDS) is a severe critical condition with a high mortality that is currently in focus given that it is associated with mortality caused by coronavirus disease 2019 (COVID-19). Neutrophils play a key role in the lung injury characteristic of non-COVID-19 ARDS and there is also accumulating evidence of neutrophil mediated lung injury in patients who succumb to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Methods: We undertook a functional proteomic and metabolomic survey of circulating neutrophil populations, comparing patients with COVID-19 ARDS and non-COVID-19 ARDS to understand the molecular basis of neutrophil dysregulation.

Results: Expansion of the circulating neutrophil compartment and the presence of activated low and normal density mature and immature neutrophil populations occurs in ARDS, irrespective of cause. Release of neutrophil granule proteins, neutrophil activation of the clotting cascade and upregulation of the Mac-1 platelet binding complex with formation of neutrophil platelet aggregates is exaggerated in COVID-19 ARDS. Importantly, activation of components of the neutrophil type I interferon responses is seen in ARDS following infection with SARS-CoV-2, with associated rewiring of neutrophil metabolism, and the upregulation of antigen processing and presentation. Whilst dexamethasone treatment constricts the immature low density neutrophil population, it does not impact upon prothrombotic hyperinflammatory neutrophil signatures.

Conclusions: Given the crucial role of neutrophils in ARDS and the evidence of a disordered myeloid response observed in COVID-19 patients, this work maps the molecular basis for neutrophil reprogramming in the distinct clinical entities of COVID-19 and non-COVID-19 ARDS.

Author list:

Affiliations

  1. Centre for Inflammation Research, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, EH16 4TJ, UK
  2. Division of Cell Signalling and Immunology, University of Dundee, Dundee, DD1 5EH, UK
  3. Anaesthesia, Critical Care and Pain, University of Edinburgh, Royal Infirmary of Edinburgh, Edinburgh, EH16 4TJ, UK
  4. Centre for Gene Regulation and Expression, University of Dundee, Dundee, DD1 5EH, UK
  5. The University of Edinburgh MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK
  6. Laboratory of Angiogenesis and Vascular Metabolism, Vesalius Research Centre, Leuven, Belgium
  7. NHS Lothian, Respiratory Medicine, Edinburgh Lung Fibrosis Clinic, Royal Infirmary, Edinburgh, EH16 4SA, UK

 

* Equal contributors

Leila Reyes1*, Manuel A. Sanchez-Garcia1*, Tyler Morrison1*, Andy J. M. Howden2*, Emily R. Watts1, Simone Arienti1, Pranvera Sadiku1, Patricia Coelho1, Ananda S. Mirchandani1, Ailiang Zhang1, David Hope3, Sarah K. Clark3, Jo Singleton3, Shonna Johnston1, Robert Grecian1, Azin Poon1, Sarah McNamara1, Isla Harper1, Max Head Fourman3, Alejandro J. Brenes2,4, Shalini Pathak2, Amy Lloyd2, Giovanny Rodriguez Blanco5, Alex von Kriegsheim5, Bart Ghesquiere6, Wesley Vermaelen6, Camila T. Cologna6, Kevin Dhaliwal1, Nik Hirani1,7, David H. Dockrell1, Moira K. B. Whyte1, David Griffith3, Doreen A. Cantrell2, Sarah R. Walmsley1